Keratoacanthoma is the epidermal tumor characterized by the benign course such as rapid growth and spontaneous resolution. Rarely keratoacanthoma invades adjacent structures. Therefore, controversies have arisen about the biologic behavior whether keratoacanthoma is a benign tumor or a variant of low grade cutaneous squamous cell carcinoma. We report a case of the recurred keratoacanthoma at the nasal vestibule treated with the surgical excision and the reconstruction by local bilobed rotation flap in a 54-year old female whose final pathology was confirmed as well differentiated squamous cell carcinoma.
Carcinoma, Squamous Cell ; Female ; Humans ; Keratoacanthoma* ; Pathology

Humans ; Esophageal Squamous Cell Carcinoma ; Esophageal Neoplasms/pathology* ; Consensus ; Carcinoma, Squamous Cell/pathology* ; Biopsy

Humans ; Esophageal Squamous Cell Carcinoma ; Carcinoma, Squamous Cell/pathology* ; Esophageal Neoplasms/pathology*

BACKGROUND AND OBJECTIVES: It is known that a part of laryngeal premalignant lesions progresses to an invasive carcinoma. Despite many previous reports, conventional histology is not sufficient to predict such tumor progression. Herein, the authors investigated the role of CD44v3 as a biomarker in predicting the progression of laryngeal premalignant lesion to an inavasive cancer. SUBJECTS AND METHOD: Paraffin-embedded tissue specimens from 40 patients were diagnosed accordingly as laryngeal invasive squamous cell carcinoma (n=10), Carcinoma in situ (n=10), dysplasia (n=10), and hyperkeratosis (n=10) between 1993 and 2002. They were immunohistochemically stained for CD44v3 protein. RESULTS: In invasive squamous cell carcinoma, the expression of CD44v3 was diffused and gave a strong positive stain, and in carcinoma in situ, it was diffused and gave 3+-2+ stain. However, in dysplasia and hyperkeratosis, the proportion of CD44v3 expression was decreased by 2+-1+, and 1+-0, respectively. CONCLUSION: These results suggest that the expression of CD44v3 in laryngeal premalignant and malignant lesions can be associated with tumorigenesis and invasion. Those strong positive expressions of CD44v3 may represent more aggressive pathology of the larynx.
Carcinogenesis ; Carcinoma in Situ ; Carcinoma, Squamous Cell ; Humans ; Larynx* ; Pathology

Carcinoma, Squamous Cell ; diagnosis ; Carcinoma, Verrucous ; diagnosis ; Epidermis ; pathology ; Humans

Carcinoma, Squamous Cell ; genetics ; pathology ; Esophageal Neoplasms ; genetics ; pathology ; Humans

BACKGROUND AND OBJECTIVES: Gap junctional intercellular communication (GJIC) is a mechanism for direct cell to cell signalling and is mediated by gap junctions, which consist of transmembrane proteins called connexins (Cxs). The authors investigated the role of connexin 26 as a biomarker that helps diagnose laryngeal squamous cell lesions. SUBJECTS AND METHOD: Paraffin-embedded tissue specimens from 50 patients, who were diagnosed with laryngeal invasive squamous cell carcinoma (n=15), carcinoma in situ (n=10), dysplasia (n=15), and non-neoplastic epithelial hyperplasia (n=10) between 1993 and 2005, were immunohistochemically stained for connexin 26 protein. RESULTS: Intracytoplasmic positive expression of connexin 26 was found in 100% of invasive squamous cell carcinoma and in 20% of carcinoma in situ. However, in dysplasia and hyperplasia, there were no positive expressions. Moreover, the majority of intercellular or membranous staining tended to decline in dysplasia, carcinoma in situ, and squamous cell carcinoma. CONCLUSION: These results suggest that aberrant expression of connexin 26 in laryngeal squamous cell lesions can be associated with tumorigenesis and invasion. Further studies are needed to investigate these expressions of connexin 26 and that it may represent more aggressive pathology of the larynx.
Carcinogenesis ; Carcinoma in Situ ; Carcinoma, Squamous Cell ; Connexins ; Gap Junctions ; Humans ; Hyperplasia ; Larynx* ; Neoplasms, Squamous Cell ; Pathology

Humans ; Squamous Cell Carcinoma of Head and Neck ; Neoadjuvant Therapy ; Head and Neck Neoplasms ; Carcinoma, Squamous Cell/pathology* ; Immunotherapy

Humans ; Squamous Cell Carcinoma of Head and Neck ; Tumor Microenvironment ; Carcinoma, Squamous Cell/pathology* ; Head and Neck Neoplasms

Humans ; Esophageal Squamous Cell Carcinoma ; Esophageal Neoplasms/pathology* ; Carcinoma, Squamous Cell ; Microbiota